Blog
The Queen of Soul
The Queen of Soul, Aretha Franklin, passed away on August 16, 2018. At the time of her death, according to probate filings by her sons, Ms. Franklin died without a will (what lawyers call “intestate”).
Amyloid Hypothesis Debate
There’s a long-running debate over the cause of Alzheimer’s disease. Just last week, we reported on a breakthrough in the in-development drug BAN2401 that appears to weigh heavily in favor for one side of the debate.
FURTHER EXPLORATION: Herpes Virus Linked to Alzheimer’s Disease
An intricate new study published in late June in Neuron revealed that certain viruses are not only most common in the brains of people with Alzheimer’s, but that they play a direct role in the chain of events responsible for the fatal neurodegenerative disorder.
BREAKING: Alzheimer’s Association suggests Exploration of Cannabinoid Treatment for Alzheimer’s Sufferers
The hallmarks of Alzheimer’s and dementia-related conditions are memory and thinking problems. However, it is the behavioral and psychological symptoms of dementia, primarily agitation, anxiety, apathy, depression, wandering, hallucinations, and incontinence that prove the greatest challenges for caregivers. It is these “symptoms” that often lead to placement in assisted living or nursing homes....
Alzheimer’s From a New Light
The search is on for new drugs to slow the progression of Alzheimer’s, and while there have been some recent breakthroughs, we are still many years away from promising drugs being on the market. In the meantime, caretakers are left with the task of working around the condition and trying to find ways to alleviate sufferers’ symptoms. Enter light therapy. In a new study shared at the Alzheimer's...
The Crusade Continues for Effective Alzheimer’s Drugs
The biggest breakthrough, which we reported on last week, was Biogen’s clinical trial results for BAN2401, the first anti-amyloid drug to receive positive later stage Alzheimer’s results. However, Biogen’s drug release into the market is still far away, with a phase three trial not expected until late 2019 or 2020. Biogen researchers pointed out that the results showed the drug could slow the cognitive decline associated with Alzheimer’s, but it did not stop the decline or reverse it.